J Natl Cancer Inst Monogr by Stroup, Antoinette M. et al.
The Impact of State-Specific Life Tables on Relative Survival
Antoinette M. Stroup,
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Division of Cancer Epidemiology, 
Department of Epidemiology, Rutgers School of Public Health, Rutgers, the State University of 
New Jersey, Piscataway, NJ
Hyunsoon Cho,
Data Modeling Branch, Surveillance Research Program, Division of Cancer Control and 
Population Sciences, National Cancer Institute, National Institutes of Health Bethesda, MD; 
Division of Cancer Registration and Surveillance, National Cancer Center, Goyang-si Gyeonggi-
do, Korea
Steve M. Scoppa,
Information Management Services, Inc., Calverton, MD
Hannah K. Weir, and
Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and 
Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA
Angela B. Mariotto
Data Modeling Branch, Surveillance Research Program, Division of Cancer Control and 
Population Sciences, National Cancer Institute, National Institutes of Health Bethesda, MD
Abstract
Background—Relative survival is based on estimating excess cancer mortality in a study 
population compared to expected mortality of a comparable population without cancer. In the 
United States, expected mortality is estimated from national life tables matched by age, sex, race, 
and calendar year to each individual in the study population. We compared five-year relative 
survival using state life tables to five-year relative survival using US decennial life tables. We 
assessed variations by age, race, and cancer site for all cancers combined, lung, colorectal, 
prostate, and female breast cancers.
Methods—We used data from 17 National Cancer Institute Surveillance, Epidemiology, and End 
Results Program registries, including diagnoses from January 1, 2000 to December 31, 2009 with 
follow-up through December 31, 2010. Five-year relative survival was calculated using US-based 
life tables (USLT) and state-specific life tables (SLT).
Results—Differences in SLT- and USLT-based survival were generally small (SLT < 4 survival 
percentage points lower than USLT). Differences were higher for states with high SES and low 
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mortality and for prostate cancer. Differences were largest for all cancers combined, colon and 
rectum, and prostate cancer among males aged 85+ ranging from −10 to −17 survival points for 
whites and +9 to +17 for blacks.
Conclusion—Differences between relative survival based on USLT and SLT were small and 
state-based estimates were less reliable than US-based estimates for older populations aged 85+. 
Our findings underscore the need to develop more appropriate life tables that better represent the 
varying mortality patterns in different populations in order to obtain accurate estimates of relative 
survival.
There is little debate that measures of survival are a valuable tool available to clinicians, 
epidemiologists, and public health professionals (1). First proposed by Ederer et al. (2) 
relative survival compares the survival probabilities of a diseased population (ie, cancer 
patients) to the survival probabilities of the general population. The resulting value, known 
as relative survival, is the ratio of observed survival to expected survival which represents 
the excess mortality associated with a cancer diagnosis. Relative survival is often used as the 
primary measure in population-based descriptive studies as in general it provides a more 
reliable estimate of the net survival from cancer than cause-specific survival because it does 
not rely on death certificate information, which is generally prone to errors in the coding of 
cause of death and has been shown to have high degrees of misclassification for cancer 
causes of death (3–5). Unlike crude probabilities of death, net survival represents cancer 
survival in the absence of competing risks (6). In this issue, Howlader et al. (7) and Mariotto 
et al. (8) further discuss differences between net and crude survival measures.
A key challenge of relative survival is in choosing the population with which to compare to 
the cancer cohort or in choosing the best life tables to represent the background mortality of 
the study population. There is a growing body of research questioning the accuracy of 
relative survival estimates that use life tables from populations that are either not 
comparable to the cancer cohort [eg, background mortality risk is substantially higher or 
lower than the cancer cohort, misclassification or unmeasured factors such as race/ethnicity 
that contribute to differential death rates in the comparison population (9–11)] or when the 
reference population has a high rate of deaths due to cancer (12).
In the United States, researchers using cancer surveillance data from the Surveillance 
Epidemiology and End Results (SEER) Program often use the US population life tables as 
the reference group for relative survival estimates, matched by age, sex, race, and calendar 
year to the cancer cohort (13). The use of US population life tables in and of itself is not 
necessarily a problem if the cancer cohort has comparable background death rates and 
characteristics. However, we know that background mortality varies by sex, age, race, and 
geographic areas as well as socioeconomic status (SES) (14–16).
The use of national life tables to calculate state-specific or regional survival has 
overestimated relative survival in states with lower background death rates and 
underestimated relative survival in states with higher background death rates (9). Baili et al. 
(9) reported that even after matching on age, sex, year, and race, relative survival for several 
US states and regional registry populations were systematically higher when using US-
matched life tables compared to the relative survival estimates using SLT [aka: the 
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CONCORD approach (9)]. The only exception was found in Louisiana, which had higher 
US-matched relative survival estimates as compared to its state-matched relative survival 
estimates. The authors attributed these differences to the lower background death rates in all 
states/regions in their study with the exception of Louisiana, which had higher background 
death rates. Moreover, for early stage prostate and breast cancer, relative survival has been 
shown to be higher than 100%, indicating that the life tables may not be appropriate for 
representing survival from other causes when examining cancer survival for these 
populations (9).
With the recent release of the 2000 state decennial life tables by the National Center for 
Health Statistics (NCHS) (17), this study expands on the work by Baili et al. (9) by 
comparing five-year relative survival using state- or regionally-matched life tables to US-
matched five-year relative survival, focusing on a more contemporary cohort of cancer 
patients diagnosed from 2000 to 2009. We also examine the underlying characteristics of 
each state/region to identify potential root causes of variations in survival estimates and 
assess the variations in survival estimates by age, race, and cancer site for lung and bronchus 
cancer, colorectal cancer, prostate cancer, and female breast cancer.
Methods
Study Population
We used cancer surveillance data from 17 states/regions that are a part of the SEER 
Program, including the states of California, Connecticut, Georgia, Hawaii, Iowa, Kentucky, 
Louisiana, New Jersey, New Mexico, and Utah; and, the metropolitan areas of Detroit and 
Seattle. The cancer cohort included individuals who were diagnosed from January 1, 2000 to 
December 31, 2009 with follow-up through December 31, 2010. We excluded cancer 
patients whose initial date of diagnosis was derived solely from death certificates or at 
autopsy and patients who were alive but without sufficient follow-up time for analysis (eg, 
survival time of 0 days), and restricted analyses to the only cancer (sequence 00) or the first 
of multiple primary diagnoses (sequence 01).
Male and female cancer patients of all races and ages were included if they were diagnosed 
with a primary malignant cancer as defined by the International Classification of Diseases 
for Oncology Second Edition, Third Edition (ICD-O-3) (18) for site and histology and 
SEER Behavior Recode for Analysis for malignancy (http://seer.cancer.gov/behavrecode/). 
SEER Behavior Recode for Analysis was used to account for changes in behavior coding, 
starting with 2001 diagnoses. We chose SEER Behavior Recode for Analysis of 3 
(malignant), which meant that cancers were classified as malignant in both ICD-O-3 and its 
predecessor ICD-O-2. SEER Site Recode, which is based on ICD-O-3 site and histology 
definitions, were used to identify the four specific cancer sites (http://seer.cancer.gov/
siterecode/icdo3_dwhoheme/index.html).
Regional and State Population Characteristics
We examine the underlying characteristics of each of the 12 states and 2 regions (Detroit 
and Seattle) with SEER registries, identifying potential root causes of in variations survival 
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estimates, by race/ethnicity, age, cancer staging and mortality, and tobacco use using several 
sources. Median age by sex and race distributions were collected from the 2000 Census (19) 
for each state and region. Cancer death rates and the percent of cancer cases diagnosed at 
localized stage for each region/state were obtained using SEER*Stat (20,21). Mortality data 
included deaths from any malignant neoplasm from 2000 to 2009 for both sexes and all 
races. Rates per 100 000 were age-adjusted to the 2000 US Standard Population. The 
percent of malignant cancers diagnosed at localized stage was identified using SEER 
Summary Stage 2000, and are defined as cancers that are confined to the original organ site 
(22). Finally, we used 2000 data from the Centers for Disease Control and Prevention’s 
(CDC) Behavioral Risk Factor Surveillance System (BRFSS) to describe the prevalence of 
tobacco use (23), which is associated with higher morbidity and mortality rates in the 
underlying population (9). BRFSS surveys are a cross-sectional, state-based cluster sample 
of individuals identified via random-digit dialing. Prevalence of tobacco use was defined as 
the percent of respondents who smoked at least 100 cigarettes in their lifetime and were 
current smokers at the time of the survey.
Cause of Death
Cancer registries use an algorithm to assign a single, disease-specific, underlying cause of 
death using information from death certificates. In some cases, attribution of a single cause 
of death may be difficult and misattribution may occur (eg, a death may be erroneously 
coded to the site of the metastasis). To capture deaths related to the specific cancer but not 
coded as such, SEER created an improved algorithm to calculate cause of death, the SEER 
cause-specific death classification variable (http://seer.cancer.gov/causespecific/) that takes 
into account causes of deaths in conjunction with tumor sequence (ie, only one tumor or the 
first of subsequent tumors), site of the original cancer diagnosis, comorbidities [eg, AIDS 
and/or site-related diseases (3)].
Life Tables
In this study, we used two sets of life tables: US-based life tables (USLT) and state-specific 
life tables (SLT). Both sets of life tables were constructed using decennial life tables from 
the NCHS and an interpolation method to calculate life tables for the individual years 
between the census years. The USLT have been the default life tables used in SEER*Stat to 
calculate relative survival for the SEER registries. The method used to derive them is 
described in detail at http://seer.cancer.gov/expsurvival/. Recently NCHS published 1999–
2001 decennial SLT for all races, whites, and, for most states, blacks (17). Life tables for 
blacks in Hawaii and Utah were not available because of extremely small black populations.
Statistical Analysis
Relative survival was calculated by actuarial methods as the ratio of all-cause survival and 
expected survival. Although relative survival could be adjusted when relative cumulative 
survival increased from a prior interval or was over 100%, we report unadjusted estimates in 
order to compare rates. Differences based on adjusted estimates were similar to the 
unadjusted. Expected survival is estimated using both the USLT and SLT by matching the 
survival cohort on age, sex, and race and year. Life tables for all races combined were 
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matched to individuals with unknown or unspecified races. Individuals were matched by the 
state of registration to the specific SLT.
Cancer-specific survival (CS) was calculated using the SEER cause-specific death 
classification variable. The events of interest were defined as deaths attributed to the cancer 
using the SEER cause-specific death classification variable (http://seer.cancer.gov/
causespecific/), and deaths due to other causes were censored. Significance was determined 
at P values less than .05 and 95% confidence intervals (CIs) are presented where 
appropriate. Analyses were conducted using SEER*Stat software.
Results
Although blacks accounted for just 12.3% of the total US population in 2000, they 
accounted for as much as 32.5%, 28.7%, and 25% of the population in Louisiana, Georgia, 
and Detroit, respectively (Table 1). Most SEER regions fell within 1–2 years of the US 
median age of 34 years for men and 36.5 years for women.
The background age-adjusted cancer death rate in the US from 2000 to 2009 was 185.5 per 
100 000 (95% CI: 185.4 to 185.7) (Table 1). Kentucky (KY) and Louisiana (LA) had the 
two highest age-adjusted cancer death rates among all SEER states/regions at 217.7 (95% 
CI: 216.3 to 219.1) and 213.8 (95% CI: 212.5 to 215.2), respectively. With the exception of 
Michigan women (22.4%), they also have some of the highest prevalence rates of current 
smokers (KY men 33.4%; LA men 26.8%; KY women 27.9%; LA women 21.7%). Utah had 
the lowest cancer mortality at 135.1 (95% CI: 133.5 to 136.8) and the lowest tobacco use 
(men 14.5%, women 11.3%).
The percent of all malignant cancers diagnosed at localized stage from 2000 to 2009 was 
44.8% in the United States (SEER 17). The state with the lowest percentage was Kentucky 
at 42.9% and the state with the highest percentage was Utah at 51.9%.
Five-Year Cancer Survival Comparisons
Five-year cause-specific survival and relative survival estimates using SLT and USLT for 
males diagnosed from 2000 to 2009 are described in Table 2 for all cancers combined, 
colorectal, lung and bronchus, and prostate cancers. Overall, differences in relative survival 
were small. For all SEER 17 regions combined, relative survival based on SLT was 
approximately 1 (%) point lower than survival based on USLT for all cancers (−0.9), 
colorectal (−1.1), and prostate (−1.2). Utah and Connecticut had the most pronounced 
differences at −2.3 and −2.2 points, respectively. In the two states with the highest cancer 
death rates, Kentucky and Louisiana, SLT relative survival was statistically significantly 
higher than USLT relative survival: +1.1 and +1.2 points, respectively. The differences 
between SLT and USLT relative survival followed the same pattern for prostate cancer but 
the differences were more pronounced in Utah (−3.5), Connecticut (−3.3), and Louisiana 
(+2.8). There were no significant differences between SLT and USLT relative survival for 
lung cancer and few significant differences for colorectal cancer.
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We saw similar patterns for women, although differences were generally smaller (Table 3). 
SLT-derived and USLT-derived survival differences were most pronounced in Connecticut 
for all cancers combined (−1.7), colorectal cancer (−3.5), and breast cancer (−2.0) when 
compared to other SEER regions. There were more significant differences between SLT and 
USLT relative survival estimates for colorectal cancers among women as compared to men, 
ranging from −2.4 in Los Angeles County to −3.5 in Connecticut.
For men diagnosed at younger ages (<75) differences between relative survival estimates 
using USLT as compared to SLT were small (Figures 1A–D). However, in the older age 
groups (aged 85+), there were substantial differences in survival. Among white males, SLT-
based relative survival for all sites combined, colorectal, and prostate cancer were 10, 12, 
and 17 points lower than USLT-based relative survival, respectively. For black males, there 
were also marked differences but in the opposite direction: 10, 9, and 17 points higher for all 
sites combined, colorectal, and prostate cancer, respectively. Furthermore, and counter to 
known prostate cancer racial disparities between blacks and whites (25), the five-year 
relative survival generated using SLT for whites aged 85 and older was lower (63%) than 
blacks (81%).
Five-year relative survival estimates based on SLT were consistently lower than those based 
on USLT across all cancer sites for black and white women aged 85 and older (Figure 2A–
D). Marked differences were found for colorectal (−11) and breast (−17) cancer among 
white women, whereas the differences for blacks were only −6 and −10 survival points, 
respectively. Unlike the pattern we saw for black and white men, white women had 
consistently higher survival rates than black women.
Discussion
By using recently published SLT (17) this study expanded the work by Baili et al. (9) by 
comparing five-year relative survival using state- and regionally-matched life tables to 
traditional US-matched five-year relative survival. We hypothesized that relative survival 
using SLT would yield more accurate estimates than relative survival using USLT because it 
takes some state variability in background mortality into account. Indeed, we found that for 
states with higher background mortality (lower survival) than the United States (ie, 
Kentucky, Louisiana, and Georgia), relative survival using SLT were generally higher than 
relative survival using USLT. In other words, the relative survival estimates based on USLT 
were underestimated. For states with lower background mortality (higher survival) than the 
United States (ie, Utah, Connecticut) relative survival using SLT were generally lower than 
relative survival using USLT (overestimated). These findings support those of Baili et al. 
(9).
We would have expected to see a larger degree of overestimation in Hawaii as it has one of 
the lowest cancer death rates among SEER program registries. The null finding for blacks in 
Hawaii was not surprising as SLT for blacks in Hawaii were not available and we used 
USLT for that group, and whites only account for 24% of the population. Future research 
will include developing life tables for Asian/Pacific Islanders and Hispanics as well as by 
socioeconomic status.
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When we examined the variability in relative survival by race and age, we found that among 
older populations (aged 85+), SLT were not as reliable as USLT. SLT for ages 85 and older 
were not derived from observed data but were extrapolated from a statistical model (17) 
since population and vital statistics data for single ages above age 85 at the state level are 
not available. On the other hand, US decennial life tables were estimated from individual 
population and mortality data up to age 100 and augmented with Medicare data to better 
ascertain age at death of older patients who may have had misreported age from death 
certificates (26). Post hoc analysis of conditional life expectancies after age 85 calculated 
from SLT (Figure 3 dots) compared to the ones calculated from USLT (Figure 3 line) 
supported our findings, wherein substantial variability exists in these older ages, especially 
among the black population. For the male white population, the state-specific conditional 
life expectancies after 85 years clearly show a bias since for all states with the exception of 
Montana they are above the US value of 5.4 years. In our study, the imprecision in SLT in 
this age group resulted in erroneous relative survival estimates that ran counter to known 
relationships between race and cancer survival (eg, black males aged 85+ had higher 
prostate cancer survival than white males in the same age group). This finding underscores 
the need for more effective approaches to estimating life tables at the state or regional level, 
and draws attention to the challenge investigators face in generating life tables for smaller 
geographic units.
SLT for blacks in Utah and Hawaii could not be created due to small population sizes. This 
was borne out in the results as cause-specific survival in Utah and Hawaii was higher than 
relative survival estimates due to their lower cancer death rates. We were also unable to 
evaluate the effect of SLT for other minority populations including Hispanics, although 
some work is currently being done to generate life tables for other underserved populations 
including Native Americans/Alaskan Natives (27) and Appalachian populations (28).
An important caveat to our study is that while some differences in relative survival were 
statistically significant, the absolute differences between each of the measures only varied 
by a few (<5) percentage points and, therefore, were not materially significant. However, we 
only controlled for sex, age, and race in this study. There is some evidence to suggest that 
other sociodemographic or socioeconomic (SES) factors may impact relative survival 
estimates (29,30). It is possible that we would have found larger differences in relative 
survival if state/regional life tables were available for SES subgroups in addition to sex, age, 
and race/ethnicity. And, given the high degree of socioeconomic disparities in the United 
States (31–33), future studies of cancer survival should consider accounting for SES 
differences. Caution should be taken to refrain from making state or regional comparisons as 
survival estimates were not age-standardized.
Howlader et al. (3) showed that cause-specific survival may be a better estimate for cancer 
sites with effective screening or that tend to be diagnosed at earlier stages, such as cancers of 
the breast, prostate, colon and rectum, and melanoma. Cho et al. (34) later confirmed these 
findings for breast and prostate cancers, providing evidence that men and women diagnosed 
with these cancers at early stages have better health status than the US population; therefore, 
relative survival based on the expected survival estimated from the USLT would be biased. 
For states with high screening uptake and medical care utilization, the death rates may be 
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lower and therefore lead to overestimates in relative survival when using USLT. Indeed, we 
found this to be true for male prostate and female breast cancers. With notable exceptions in 
Kentucky and Louisiana which have the highest cancer death rates among the SEER 
registries, relative survival using SLT is lower than relative survival using USLT and closer 
to cause-specific survival. For cancers with poor prognosis, such as lung cancer, we found a 
similar underestimation previously reported by Howlader et al. (3) as USLT produced lower 
survival estimates as compared to cause-specific survival (Figures 1 and 2). In our study, we 
found the same bias using SLT, which resulted in very similar estimates. The similarities in 
relative survival estimates for lung cancer is likely due to the fact that the same biases 
present in the USLT remain in SLT. Namely, that the expected survival estimated from the 
life table for lung cancer cohorts overestimates their actual other-cause survival given the 
higher prevalence of smoking and other comorbid conditions in this population than either 
the US or the state comparison populations (2,34).
Our study is one of the first comprehensive assessments of survival estimates generated 
using three approaches. Overall differences between relative survival based on USLT and 
SLT tended to be small but in the direction we would expect; however, some differences 
were large, particularly among older populations aged 85 and older where data were sparse. 
Generally, SLT should not be used to estimate relative survival for ages 85 and up, but 
might provide slightly better relative survival estimates for specific cancer types. Our 
findings underscore the need for continued development of life tables that better describe 
life expectancy for ethnic minorities, older age groups, and other regional, geographic, and 
socioeconomic subgroups.
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Five-year survival probability comparisons for males by cancer site, age, and race SEER-17 
(2000-2009). Relative survival based on state-specific life tables (SLT) and US-based life 
tables (USLT). CS = cause-specific survival.
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Five-year survival probability comparisons for females by cancer site, age, and race 
SEER-17 (2000-2009). Relative survival based on state-specific life tables (SLT) and US-
based life tables (USLT). CS = cause-specific survival.
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Comparison of 2000 decennial National Center for Health Statistics (NCHS) state life and 
US tables. Dots represent life expectancy estimated from state life tables. The vertical line 
represents the life expectancy estimated from US national life tables.
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